News – Page 971 – Endpoints News

FDA offers Pfizer priority review for tafamidis; Clarivate to merge with Churchill Capital

7 years ago

Is JPM worth it? As the buzzy conference dies down, debate on its value rumbles on

7 years ago

FDA staff largely unfazed by CV signal in Amgen osteoporosis drug trials

7 years ago

Buzz: This little biotech has so much going against it, somebody is going to want to buy it. Right?

7 years ago

CMO Sean Bohen joins exodus at AstraZeneca during a major R&D leadership overhaul

7 years ago

Nebulizer fails PhII COPD study, but Verona plans to march on

7 years ago

Parker-backed cancer scientists shine a light on an emerging pathway in pancreatic cancer

7 years ago

Kaleido, Cirius brace the IPO market seeking a combined $186M — despite barriers at shutdown-mode SEC

7 years ago

Aslan turns focus to biliary tract cancer as lead drug flops in PhII gastric cancer study

7 years ago

Ironwood recruits CMO on the eve of split-up; Roche vet Margrit Schwarz joins Genevant

7 years ago

Early research suggests existing drugs could strangle building blocks of metastasis

7 years ago

So what did we learn from JPMorgan week? Buckle up, it’s going to be a bumpy ride

7 years ago

Anti-aging startup Elevian enlists Insilico on AI quest for 'young blood'

7 years ago

Computational scientists design a new IL-2 cancer drug and spin it out into a biotech startup

7 years ago

J&J hikes US prices for a basket of drugs, including certain top-sellers — Reuters

7 years ago

As JPMorgan madness subsides, Democrats will unveil a legislative package to address drug price hikes

7 years ago

CANbridge expands rare disease pact with WuXi Biologics; Watch for a manufacturing site from Allogene

7 years ago

AstraZeneca chops 210 workers, closes sites as it looks to concentrate biologics manufacturing in one place

7 years ago

NICE rejects Novartis' migraine drug Aimovig, months after declining to endorse pricey Kymriah for adult use

7 years ago

Roche exec Pearl Huang rejoins biotech as CEO of Cygnal — Flagship's bet on 'exoneural biology'

7 years ago

Betting on allosteric mutations driving cancer, Black Diamond raises $85M in fresh round

7 years ago

The first patient has been treated under the controversial 'right to try' law

7 years ago

Roche names new Foundation Med chief; Akorn shares dip on FDA warning letter; Zai Lab advances pivotal PARP study

7 years ago

Denali broadens tech to infiltrate the blood-brain barrier with Sirion deal

7 years ago

First page Previous page 968 969 970971972 973 974 Next page Last page